Cocrystal Pharma, Inc. focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases.It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection.
